Immunic secures $400M to support late-stage MS trials - ICYMI [Yahoo! Finance]
Immunic, Inc. (IMUX)
Company Research
Source: Yahoo! Finance
Immunic Inc (NASDAQ:IMUX) earlier this week outlined how a newly secured up to $400 million private placement is set to support completion of late-stage trials and prepare the company for a potential commercial launch of vidofludimus calcium in multiple sclerosis. Speaking to Proactive, CEO Dr Daniel Vitt described the financing as “a transformative transaction for the company,” noting that $200 million has already been received, with the remainder available in a second tranche. He said the raise equips the company with the flexibility required to transition into a commercial-stage organization as it approaches a pivotal data milestone. The primary near-term catalyst is the Phase 3 ENSURE program in relapsing multiple sclerosis (RMS), comprising two twin studies. Vitt confirmed that an interim analysis conducted in 2024 resulted in the Independent Data Monitoring Committee recommending the trials continue as planned. Topline data from the four-year, 2,200-patient program is e
Show less
Read more
Impact Snapshot
Event Time:
IMUX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMUX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMUX alerts
High impacting Immunic, Inc. news events
Weekly update
A roundup of the hottest topics
IMUX
News
- Immunic to Participate in Investor Conferences in MarchPR Newswire
- Immunic (IMUX) had its price target lowered by HC Wainwright from $8.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- Immunic sets stage for phase 3 MS data readout after $400M financing [Yahoo! Finance]Yahoo! Finance
- Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate UpdatePR Newswire
IMUX
Earnings
- 11/13/25 - Beat
IMUX
Analyst Actions
- 2/9/26 - HC Wainwright
IMUX
Sec Filings
- 3/4/26 - Form SCHEDULE
- 3/4/26 - Form D
- 3/2/26 - Form DEF
- IMUX's page on the SEC website